Vertaling van "for the reference administered " (Nederlands → Frans) :

Guidelines for the Reference Administered Activities approved by the working group of the Belgian Society for Nuclear Medicine
Guidelines for the Reference Administered Activities approved by the working group of the Belgian Society for Nuclear Medecine

The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference
The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

The clinical significance of heterogeneous glycopeptide intermediate S. aureus (hGISA; borderline susceptible strains) is unclear, although recent data suggest that the response to the glycopeptide therapy administered to patients infected by such variants can be poor.
La signification clinique de S. aureus intermédiaire aux glycopeptides hétérogènes (hGISA; les souches sensibles limites) est peu claire bien que les données récentes suggèrent que la réponse à la thérapie aux glycopeptides des patients infectés par de telles variantes peut être insuffisante.

Moreover, these patients rarely heed the referral to other specialists or the treatment administered for underlying problems after having been treated in the emergency service. In this project, the GPs are asked to actively follow the patients and to encourage them to receive post-hospital follow-up care (possibly provided by the hospital).
Dans ce projet, il est demandé au médecin généraliste de suivre le patient activement et de l’encourager à profiter du suivi post-hospitalier (éventuellement proposé par l’hôpital).

Though the quality of the somatic and medical care administered upon admittance does not differ from that provided for other emergencies, we do know that there are a series difficulties involved in the manner in which suicidal patients are to be managed and that these difficulties are not or badly taken into account by some emergency services:
Si la prise en charge somatique et les soins médicaux qui sont posés lors de cette admission ne diffèrent pas des autres situations d’urgence en qualité, nous savons que la prise en charge de la crise suicidaire pose une série de difficultés qui elles ne sont pas ou mal prises en compte par certains services d’urgence:

5.2.3 Demonstration of MRSA eradication of known carriers Samples must be taken at least 48 hours after the last antibiotic dose was administered or after decontamination.
5.2.3 Démonstration de l’éradication de MRSA des porteurs connus Les échantillons doivent être prélevés au moins 48 heures après que la dernière dose antibiotique ait été administrée ou après la décontamination.

However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the
However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the

U kunt in dit geval een aanvraag indienen volgens de «Post-Annex I» (bestaat enkel in het Engels) procedure (= Europese procedure). BELANGRIJKE OPMERKING: U moet binnen de zes maanden na het besluit tot opname in Bijlage 1 of 1A van de Biocidenrichtlijn van de laatste «stof-PT» combinatie de Dienst Risicobeheersing van het DG Leefmilieu inlichten omtrent uw intenties rond deze Europese procedure (toelatingsaanvraag met België als «Reference Member State» of toelatingsaanvraag in een andere EU-lidstaat met wederzijdse erkenning in België, overeenkomstig artikel 7 van het koninklijk besluit van 12 maart 2010 tot wijziging van het koninklijk besluit van 22 mei 2003 betreffende het op de markt brengen en het gebruiken van biociden).
REMARQUE IMPORTANTE : dans les six mois de la décision d'inclusion dans l'annexe 1 ou 1A de la directive sur les biocides de la dernière combinaison de substance-TP, vous devez informer le service Maîtrise des risques de la DG Environnement de vos intentions au sujet de cette procédure européenne (demande d'autorisation avec la Belgique en tant qu'État membre de référence ou demande d'autorisation dans un autre État membre de l'UE avec reconnaissance mutuelle en Belgique, conformément à l'article 7 de l'arrêté royal du 12 mars 2010 modifiant l'arrêté royal du 22 mai 2003 concernant la mise sur le marché et l'utilisation des produits biocides).

De evaluatie en eventuele validatie van de analysemethoden voor additieven wordt, zoals vastgesteld in de verordening 378/2005/EG (.PDF), uitgevoerd door het EU Referentielaboratorium JRC - IRMM (Joint Research Centre - Institute for Reference Materials and Measurements) (WEB) van de Europese Commissie.
L’évaluation et l’éventuelle validation des méthodes d’analyse pour additifs est, comme prévu par le Règlement n° 378/2005/CE (.PDF), réalisé par le Laboratoire communautaire de référence JRC - IRMM (Joint Research Centre - Institute for Reference Materials and Measurements) (WEB) de la Commission européenne.